MedTrace Logo

Comparison of Cannabinoids to Placebo in Management of TMJ Pain and Myofascial Pain in the TMJ Region

NCT04298554 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2023-03-14

No results posted yet for this study

Summary

The aim of this study is to determine whether the cannabinoids taken orally in the form of cannabidiol (CBD oil-a major non-psychoactive component of marijuana) vs placebo (hemp oil) will provide pain relief and improved jaw function in those who suffer from either myofascial pain disorder and/or arthralgia of the temporomandibular region.

1. Primary Objectives To determine if the consumption of CBD oil is superior to placebo for the improvement in jaw pain.
2. Secondary Objectives To determine if the consumption of CBD oil is superior to placebo for the improvement in function of the temporomandibular joint.
3. Exploratory Objectives To determine if there are any adverse effects that result from the consumption of CBD oil or placebo.

Conditions

  • TMJ Disorder
  • Myofacial Pain
  • TMD

Interventions

OTHER

CBD Oil

CBD PURE CBD OIL 20mg/1ml concentration

OTHER

Hemp Oil

CBD PURE HEMP OIL

Sponsors & Collaborators

  • Weill Medical College of Cornell University

    lead OTHER

Principal Investigators

  • Gwendolyn Reeve, DMD FACS · Weill Cornell New York Presbyterian Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-06
Primary Completion
2022-05-29
Completion
2022-05-29

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04298554 on ClinicalTrials.gov